Did salvage ICE chemotherapy improve the outcome in primary resistantrelapsing stage III IV neuroblastoma?

المؤلفون المشاركون

Abd al-Rahman, Hani
al-Debawy, Iman
Mustafa, Najla A. E.
Musa, Imad A. H.
Zikri, Wail Z. K.
Izzat, Samirah
Rayyan, Abd al-Rahman
Yunus, Ala

المصدر

Journal of the Egyptian National Cancer Institute

العدد

المجلد 23، العدد 1 (31 مارس/آذار 2011)، ص ص. 47-53، 7ص.

الناشر

جامعة القاهرة المعهد القومي للأورام

تاريخ النشر

2011-03-31

دولة النشر

مصر

عدد الصفحات

7

التخصصات الرئيسية

الطب البشري

الموضوعات

الملخص EN

Background and purpose : Neuroblastoma is the most common extra cranial and deadly solid tumor in children.

It accounts for 15 % of the deaths from cancer in the pediatric age group.

Approximately half of the newly diagnosed children are at ‘‘high risk’’ of treatment failure.

The aim of this study is to evaluate the response rate of salvage chemotherapy by the ICE (Ifosfamide, Carboplatin, and Etoposide) regimen when administered to previously treated primary refractory or progressive high risk neuroblastoma patients.

Patients and methods: Sixty-six patients from the National Cancer Institute (NCI), Cairo University and the Children Cancer Hospital Egypt (CCHE) received salvage chemotherapy (ICE) either due to primary resistance in 51 / 66 (77.2 %) or due to disease progression on primary chemotherapy in 15 / 66 (22.8 %).

Results : they were 40 males (60.6 %) and 26 females (39.4%).

Patients’ age ranged between 3 months and 12.5 years.

The most common tumor site was suprarenal, followed by retroperitoneal mass.

Two patients (3 %) died from chemotherapy toxicity during ICE administration.

Evaluation of tumor response in the remaining 64 patients showed the following: CR/PR in 24 patients (36.5 %), SD in 11 patients (16.6 %), and PD in 29 patients (43.9 %).

Fourteen patients (21.2 %) were considered eligible for auto BMT, while 50 / 64 patients (78.8 %) failed this second line (salvage) chemotherapy and had palliative lines of therapy.

By the end of the study (May 2010), 47 / 66 (71.2 %) of the patients were still alive, while 19 / 66 (28.8 %) were dead.

Two out of 14 patients (14.2 %) who underwent HSCT died from post transplantation disease progression, while 12 / 14 (85.8 %) were in CCR.

Conclusion : chemotherapy by ICE for primary resistant or progressive stage III / IV NB seems well tolerated.

With a 36.6 % response rate, 18 % CCR, and 3 % treatment mortality rate, it could be considered a good salvage therapy in the category of patients who are condemned for palliation.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Abd al-Rahman, Hani& Musa, Imad A. H.& Zikri, Wail Z. K.& al-Debawy, Iman& Mustafa, Najla A. E.& Yunus, Ala…[et al.]. 2011. Did salvage ICE chemotherapy improve the outcome in primary resistantrelapsing stage III IV neuroblastoma?. Journal of the Egyptian National Cancer Institute،Vol. 23, no. 1, pp.47-53.
https://search.emarefa.net/detail/BIM-293239

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Abd al-Rahman, Hani…[et al.]. Did salvage ICE chemotherapy improve the outcome in primary resistantrelapsing stage III IV neuroblastoma?. Journal of the Egyptian National Cancer Institute Vol. 23, no. 1 (Mar. 2011), pp.47-53.
https://search.emarefa.net/detail/BIM-293239

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Abd al-Rahman, Hani& Musa, Imad A. H.& Zikri, Wail Z. K.& al-Debawy, Iman& Mustafa, Najla A. E.& Yunus, Ala…[et al.]. Did salvage ICE chemotherapy improve the outcome in primary resistantrelapsing stage III IV neuroblastoma?. Journal of the Egyptian National Cancer Institute. 2011. Vol. 23, no. 1, pp.47-53.
https://search.emarefa.net/detail/BIM-293239

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references : p. 52-53

رقم السجل

BIM-293239